6922 (6922) Fair Value & Analysis

Healthcare · Market cap HK$925M

6 6922 6922 · HK

PriceHK$3.78

Fair ValueHK$2.04

Upside-46.0%

Quality51/100

Watch 6922 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$1.49 – HK$3.06

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −21.3% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$3.78 – HK$7.97 · fair‑value band HK$1.49 – HK$3.06 · the HK$3.78 price screens above the HK$2.04 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6922 (6922) currently trades at HK$3.78, while our model-based Fair Value estimate is HK$2.04 — implying the stock looks roughly 46.0% overvalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 6922 generated revenue of HK$95.3M at a net margin of -40.1%. Revenue grew 29.7% year over year. It earns a return on equity of -69.8%. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$95.3M

Revenue growth (YoY) +29.7%

Net margin -40.1%

Return on equity -69.8%

Free cash flow −HK$6.6M FY2025

Operating margin -38.3%

More key figures

EPS (TTM) HK$-0.1000

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6922 reported revenue of HK$95.3M in FY2025 versus HK$22.4M in FY2021, a compound +43.6%/yr. Reported net income was −HK$38.2M in FY2025.

Revenue +43.6%/yr

FY21 HK$22.4M

FY22 HK$27.1M

FY23 HK$41.0M

FY24 HK$53.5M

FY25 HK$95.3M

Net income

FY21 −HK$102M

FY22 −HK$112M

FY23 −HK$97.5M

FY24 −HK$104M

FY25 −HK$38.2M

Is 6922 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	1,228 MXN	-23%
Abbott Laboratories, ABTT34	R$37.76	R$6.34	-83%
Stryker Corporation S1YK34	R$77.83	R$8.47	-89%
Medtronic plc MDT	$80.25	$74.40	-7%
Boston Scientific Corporation B1SX34	R$248.75	R$221.81	-11%
Edwards Lifesciences Corporation EW	$85.88	$41.02	-52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6922 (6922) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$2.04 versus a price of HK$3.78 — about −46% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 6922?

Our model-based fair value for 6922 is HK$2.04 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$3.78.

What is the quality score of 6922?

6922 has a Quality Score of 51/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6922 (6922)?

6922 reported trailing-twelve-month revenue of about HK$95.3M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6922?

The net profit margin of 6922 is about -40.1%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.